NCT06399419View on ClinicalTrials.gov

CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

June 19, 2024

Primary Completion Date

October 19, 2026

Study Completion Date

October 19, 2026

Conditions
Advanced Clear Cell Renal Cell CarcinomaAdvanced Renal Cell CarcinomaAdvanced Sarcomatoid Renal Cell CarcinomaMetastatic Clear Cell Renal Cell CarcinomaMetastatic Renal Cell CarcinomaMetastatic Sarcomatoid Renal Cell CarcinomaStage III Renal Cell Cancer AJCC v8Stage IV Renal Cell Cancer AJCC v8
Interventions
PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Bone Scan

Undergo bone scan

BIOLOGICAL

CBM588 Capsules

Given PO

PROCEDURE

Computed Tomography

Undergo CT

BIOLOGICAL

Ipilimumab

Given IV

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

BIOLOGICAL

Nivolumab

Given IV

Trial Locations (1)

91010

RECRUITING

City of Hope Medical Center, Duarte

Sponsors
All Listed Sponsors
collaborator

City of Hope Medical Center

OTHER

collaborator

Miyarisan Pharmaceuticals, Co., Ltd.

UNKNOWN

collaborator

National Cancer Institute (NCI)

NIH

lead

Osel, Inc.

INDUSTRY

NCT06399419 - CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer | Biotech Hunter | Biotech Hunter